CN113730377A - 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 - Google Patents
一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 Download PDFInfo
- Publication number
- CN113730377A CN113730377A CN202110996919.0A CN202110996919A CN113730377A CN 113730377 A CN113730377 A CN 113730377A CN 202110996919 A CN202110996919 A CN 202110996919A CN 113730377 A CN113730377 A CN 113730377A
- Authority
- CN
- China
- Prior art keywords
- parts
- drug
- tween
- diclofenac epolamine
- following components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000942 diclofenac epolamine Drugs 0.000 title claims abstract description 89
- DCERVXIINVUMKU-UHFFFAOYSA-N diclofenac epolamine Chemical compound OCC[NH+]1CCCC1.[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCERVXIINVUMKU-UHFFFAOYSA-N 0.000 title claims abstract description 89
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000003814 drug Substances 0.000 claims abstract description 80
- 229940079593 drug Drugs 0.000 claims abstract description 76
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 70
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 70
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 70
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 53
- 239000011159 matrix material Substances 0.000 claims abstract description 51
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 42
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 51
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000008213 purified water Substances 0.000 claims description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 17
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 17
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 17
- 229940048879 dl tartaric acid Drugs 0.000 claims description 17
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 17
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 17
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 17
- 229920000609 methyl cellulose Polymers 0.000 claims description 17
- 239000001923 methylcellulose Substances 0.000 claims description 17
- 235000010981 methylcellulose Nutrition 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 229940069328 povidone Drugs 0.000 claims description 17
- 239000000600 sorbitol Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- -1 polypropylene Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 239000010410 layer Substances 0.000 claims 18
- 239000012790 adhesive layer Substances 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 abstract description 19
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 230000001186 cumulative effect Effects 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 4
- 239000003623 enhancer Substances 0.000 abstract description 3
- 210000001503 joint Anatomy 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 210000004872 soft tissue Anatomy 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 20
- 230000008961 swelling Effects 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | 经皮渗透速率(μg·cm<sup>-2</sup>·h<sup>-1</sup>) | 累积渗透量(μg·cm<sup>-2</sup>) |
实施例1 | 0.72±0.07 | 13.17±0.88 |
实施例2 | 0.98±0.05 | 18.72±0.23 |
实施例3 | 0.89±0.03 | 16.64±0.36 |
实施例4 | 0.56±0.04 | 9.91±0.25 |
实施例5 | 0.55±0.09 | 9.63±0.31 |
实施例6 | 0.53±0.05 | 9.06±0.03 |
对比例1 | 0.22±0.02 | 3.52±0.13 |
对比例2 | 0.23±0.07 | 3.93±0.16 |
对比例3 | 0.10±0.04 | 1.58±0.34 |
对比例4 | 0.15±0.01 | 2.42±0.57 |
对比例5 | 0.21±0.02 | 3.49±0.49 |
对比例6 | 0.23±0.07 | 3.89±0.32 |
对比例7 | 0.28±0.06 | 4.84±0.21 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110996919.0A CN113730377A (zh) | 2021-08-27 | 2021-08-27 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110996919.0A CN113730377A (zh) | 2021-08-27 | 2021-08-27 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113730377A true CN113730377A (zh) | 2021-12-03 |
Family
ID=78733553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110996919.0A Pending CN113730377A (zh) | 2021-08-27 | 2021-08-27 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113730377A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115120577A (zh) * | 2022-08-10 | 2022-09-30 | 北京羚锐伟业科技有限公司 | 一种含有双氯芬酸的凝胶贴膏及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105395544A (zh) * | 2014-08-23 | 2016-03-16 | 南京海纳医药科技有限公司 | 双氯芬酸依泊胺凝胶制备方法及药物用途 |
CN105878214A (zh) * | 2014-08-23 | 2016-08-24 | 南京海纳医药科技有限公司 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
CN111821285A (zh) * | 2020-06-17 | 2020-10-27 | 南京海纳医药科技股份有限公司 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
-
2021
- 2021-08-27 CN CN202110996919.0A patent/CN113730377A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105395544A (zh) * | 2014-08-23 | 2016-03-16 | 南京海纳医药科技有限公司 | 双氯芬酸依泊胺凝胶制备方法及药物用途 |
CN105878214A (zh) * | 2014-08-23 | 2016-08-24 | 南京海纳医药科技有限公司 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
CN111821285A (zh) * | 2020-06-17 | 2020-10-27 | 南京海纳医药科技股份有限公司 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115120577A (zh) * | 2022-08-10 | 2022-09-30 | 北京羚锐伟业科技有限公司 | 一种含有双氯芬酸的凝胶贴膏及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1030660B1 (en) | A transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof | |
CA2098196C (en) | Method and systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers | |
JP5542665B2 (ja) | マトリックス型経皮投与剤およびその製造方法 | |
KR101601335B1 (ko) | 경피 흡수 제제 | |
US11324705B2 (en) | Transdermal drug delivery system | |
JP2001503749A (ja) | 透過促進剤としてのグリコール酸の脂肪酸エステル及びその塩 | |
JP3731016B2 (ja) | 化学的に塩基性の揮発性医療用活性物質の経皮的投与のためのプラスタおよびその製造方法 | |
JP2540019B2 (ja) | 医薬組成物 | |
AU2007200426A1 (en) | Transdermal delivery of lasofoxifene | |
JPS60152413A (ja) | メントールにより経皮性薬剤放出の強化を行なつた局所用組成物 | |
EP1894563B2 (de) | Pflaster, enthaltend Fentanylum | |
CN113730377A (zh) | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 | |
CN111821285A (zh) | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 | |
WO1998029143A1 (de) | Extrem flexibles, dermal oder transdermal wirkendes pflaster und verfahren zu seiner herstellung | |
WO1999055341A1 (en) | Transdermal administration of fenoldopam | |
JPH04273818A (ja) | 経皮投与製剤 | |
JP2000063267A (ja) | 経皮吸収貼付剤 | |
JP2002520352A (ja) | プロピルノルアポモルフィンを含有する経皮性パッチならびに局所性組成物 | |
CN107684552B (zh) | 一种依托芬那酯贴剂 | |
CN115804763A (zh) | 一种含阿赛那平的透皮贴剂 | |
JP2001039873A (ja) | 経皮吸収型排尿障害治療剤 | |
CN116712413A (zh) | 一种普拉克索透皮贴剂 | |
CN112716921A (zh) | 氨磺必利透皮贴剂 | |
EP2438912B1 (de) | Pflaster, enthaltend Fentanylum | |
KR19980027318A (ko) | 비스테로이드성 소염진통제를 함유하는 경피흡수제제와 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230612 Address after: 210009 15 Floor, No. 5 New Model Road, Gulou District, Nanjing City, Jiangsu Province Applicant after: NANJING HEALTHNICE PHARMACEUTICAL TECHNOLOGY CO.,LTD. Applicant after: Nanjing Oceanwide Pharmaceutical Technology Co.,Ltd. Applicant after: NANJING HEALTHNICE PHARMACEUTICAL CO.,LTD. Applicant after: NANJING YINUO MEDICINE TECHNOLOGY Co.,Ltd. Address before: 210009 15 Floor, No. 5 New Model Road, Gulou District, Nanjing City, Jiangsu Province Applicant before: NANJING HEALTHNICE PHARMACEUTICAL TECHNOLOGY CO.,LTD. Applicant before: NANJING HEALTHNICE PHARMACEUTICAL CO.,LTD. Applicant before: NANJING YINUO MEDICINE TECHNOLOGY Co.,Ltd. |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211203 |